Evidence map›Paper›PMID 42124693›Full record

ArticlebioRxiv : the preprint server for biology2026

eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemia.

Biljana Culjkovic-Kraljacic, Leandro Marcelo Martinez, Alyssa Retiz, Samuel Perron, Naiyu Shi, Caleb Embree, Winnie Yip, Vicenta Trujillo-Alonso, Emma Lassman, Marysol Chu Carty and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Biljana Culjkovic-KraljacicDepartment of Pathology and Cell Biology & Institute for Research in Immunology and Cancer, Université de Montréal, Québec, Canada.ORCID 0000-0003-4350-3014
Leandro Marcelo MartinezDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9283-5093
Alyssa RetizDepartment of Pharmacology and Robert H. Lurie Cancer Centre, Northwestern University, Chicago, Illinois, USA.ORCID 0000-0001-9170-9733
Samuel PerronDepartment of Pathology and Cell Biology & Institute for Research in Immunology and Cancer, Université de Montréal, Québec, Canada.
Naiyu ShiDepartment of Pharmacology and Robert H. Lurie Cancer Centre, Northwestern University, Chicago, Illinois, USA.
Caleb EmbreeDepartment of Pharmacology and Robert H. Lurie Cancer Centre, Northwestern University, Chicago, Illinois, USA.ORCID 0000-0002-7437-4510
Winnie YipDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Vicenta Trujillo-AlonsoDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Emma LassmanDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Marysol Chu CartyDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0009-0000-5347-9367
Kata AlilovicDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0009-0001-9348-6059
Sebastien CarrenoDepartment of Pathology and Cell Biology & Institute for Research in Immunology and Cancer, Université de Montréal, Québec, Canada.ORCID 0000-0002-5839-2102
Gail J RobozDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Monica L GuzmanDivision of Hematology/Medical Oncology, and Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9262-8246
Katherine L B BordenDepartment of Pathology and Cell Biology & Institute for Research in Immunology and Cancer, Université de Montréal, Québec, Canada.ORCID 0000-0003-2188-5074

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aggressive subtypes of acute myeloid leukemia (AML) are characterized by increased migratory behavior and poor prognosis prioritizing the need for uncovering relevant mechanisms. While attributed to transcriptional changes, these AMLs manifest dysregulated eIF4E implicating disrupted mRNA metabolism. Here, we observed in AML mouse models, patient specimens, and cell lines that eIF4E drives motility, colonization, engraftment and AML progression. AML cells migrate utilizing Ezrin-positive pseudopods. Unexpectedly, we discovered that eIF4E interacts with Ezrin, that these physically associated factors are required and cooperated to drive an on-demand translation program in pseudopods for motility. Indeed, pseudopods were sites of eIF4E- and Ezrin-dependent translation by implementing the first method to directly mark active ribosomes

Identifiers

PMID42124693
PMCPMC13160139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.